Available to mentor
Gil Omenn is Harold T. Shapiro Distinguished University Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics, and Public Health at the University of Michigan, Ann Arbor, USA. He served as Executive Vice President for Medical Affairs and as Chief Executive Officer of the University of Michigan Health System from 1997 to 2002. He was Dean of the School of Public Health, and Professor of Medicine and Environmental Health, University of Washington, Seattle, 1982-1997. He is the leader of the global Human Proteome Project (HPP) of the Human Proteome Organization (HUPO). His current research is focused on proteogenomics of alternative splicing in cancers. Splice variants are a major source of protein diversity in multi-cellular organisms with multi-exonic genes. Splice isoforms are good candidates for more specific biomarkers and therapeutic targets. He is author of 548 publications. Omenn has visited China 12 times since 1976. He is an honorary faculty of Peking Union Medical College, affiliate faculty of the Institute for Systems Biology in Seattle, member of the U.S. National Academy of Medicine, past president of the American Association for the Advancement of Science, board member of the Weizmann Institute of Science in Israel, and a director of several biotech companies. He served as a White House Fellow at the U.S. Atomic Energy Commission and as associate director of the White House Office of Science & Technology Policy and Office of Management & Budget. He earned the B.A. from Princeton University, M.D. from Harvard Medical School, and PhD in genetics from University of Washington. He is a musician and tennis player.
-
Center MemberRogel Cancer Center
-
Center MemberCenter for Computational Medicine and Bioinformatics
-
Center MemberInstitute for Healthcare Policy and Innovation
Dr. Omenn's research focuses on proteo-genomics of cancers and proteomics informatics. He long chaired and remains active in the Human Proteome Organization (HUPO) global Human Proteome Project (www.thehpp.org). There are datasets for application of analytical tools, and there are research teams eager to engage in collaborative studies in the Chromosome-centric HPP and Biology and Disease-driven HPP initiatives. He is a co-founder of the Consortium for Clinical Characterization of Covid-19 using Electronic Health Records (4CE) organized by the i2b2tranSMART Foundation and Harvard colleagues. He has long-standing interests in mechanisms of genetic predispositions to risks from environmental and occupational exposures (eco-genetics) and science-based risk analyses.
-
Hutch MR, Son J, Le TT, Hong C, Wang X, Shakeri Hossein Abad Z, Morris M, Gutiérrez-Sacristán A, Klann JG, Spiridou A, Batugo A, Bellazzi R, Benoit V, Bonzel C-L, Bryant WA, Chiudinelli L, Cho K, Das P, González González T, Hanauer DA, Henderson DW, Ho Y-L, Loh NHW, Makoudjou A, Makwana S, Malovini A, Moal B, Mowery DL, Neuraz A, Samayamuthu MJ, Sanz Vidorreta FJ, Schriver ER, Schubert P, Talbert J, Tan ALM, Tan BWL, Tan BWQ, Tibollo V, Tippman P, Verdy G, Yuan W, Avillach P, Gehlenborg N, Omenn GS, Consortium for Clinical Characterization of COVID-19 by EHR (4CE) , Visweswaran S, Cai T, Luo Y, Xia Z. PLOS Digit Health, 2024 Apr; 3 (4): e0000484Journal ArticleNeurological diagnoses in hospitalized COVID-19 patients associated with adverse outcomes: A multinational cohort study.
DOI:10.1371/journal.pdig.0000484 PMID: 38620037 -
Lih TM, Cao L, Minoo P, Omenn GS, Hruban RH, Chan DW, Bathe OF, Zhang H. Mol Cell Proteomics, 2024 Jan; 23 (1): 100687Journal ArticleDetection of Pancreatic Ductal Adenocarcinoma-Associated Proteins in Serum.
DOI:10.1016/j.mcpro.2023.100687 PMID: 38029961 -
Dagliati A, Strasser ZH, Hossein Abad ZS, Klann JG, Wagholikar KB, Mesa R, Visweswaran S, Morris M, Luo Y, Henderson DW, Samayamuthu MJ, Tan BWQ, Verdy G, Omenn GS, Xia Z, Bellazzi R, Consortium for Clinical Characterization of COVID-19 by EHR (4CE), , Murphy SN, Holmes JH, Estiri H, Consortium for Clinical Characterization of COVID-19 by EHR (4CE) . EClinicalMedicine, 2023 Oct; 64: 102210Journal ArticleCharacterization of long COVID temporal sub-phenotypes by distributed representation learning from electronic health record data: a cohort study.
DOI:10.1016/j.eclinm.2023.102210 PMID: 37745021 -
Sperotto F, Gutiérrez-Sacristán A, Makwana S, Li X, Rofeberg VN, Cai T, Bourgeois FT, Omenn GS, Hanauer DA, Sáez C, Bonzel C-L, Bucholz E, Dionne A, Elias MD, García-Barrio N, González TG, Issitt RW, Kernan KF, Laird-Gion J, Maidlow SE, Mandl KD, Ahooyi TM, Moraleda C, Morris M, Moshal KL, Pedrera-Jiménez M, Shah MA, South AM, Spiridou A, Taylor DM, Verdy G, Visweswaran S, Wang X, Xia Z, Zachariasse JM, Consortium for Clinical Characterization of COVID-19 by EHR (4CE) , Newburger JW, Avillach P. EClinicalMedicine, 2023 Oct; 64: 102212Journal ArticleClinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium.
DOI:10.1016/j.eclinm.2023.102212 PMID: 37745025 -
Getzen E, Tan AL, Brat G, Omenn GS, Strasser Z, Consortium for Clinical Characterization of COVID-19 by EHR (4CE) (Collaborative Group/Consortium) , Long Q, Holmes JH, Mowery D. AMIA Annu Symp Proc, 2023 2023: 942 - 950.Journal ArticleLeveraging informative missing data to learn about acute respiratory distress syndrome and mortality in long-term hospitalized COVID-19 patients throughout the years of the pandemic.
PMID: 38222425 -
Omenn GS, Eaton DL. 2022 Dec 27; Risk Assessment for Environmental Health, 15 - 38.ChapterThe risk assessment-risk management paradigm
DOI:10.1201/9780429291722-2 -
Lindsly S, Jia W, Chen H, Liu S, Ronquist S, Chen C, Wen X, Stansbury C, Dotson GA, Ryan C, Rehemtulla A, Omenn GS, Wicha M, Li SC, Muir L, Rajapakse I. iScience, 2021 Dec 17; 24 (12): 103452Journal ArticleFunctional organization of the maternal and paternal human 4D Nucleome.
DOI:10.1016/j.isci.2021.103452 PMID: 34877507 -
Huang X, Pearce R, Omenn GS, Zhang Y. Int J Mol Sci, 2021 Jun 30; 22 (13):Journal ArticleIdentification of 13 Guanidinobenzoyl- or Aminidinobenzoyl-Containing Drugs to Potentially Inhibit TMPRSS2 for COVID-19 Treatment.
DOI:10.3390/ijms22137060 PMID: 34209110